Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition

Journal of Molecular Biology

Volumn 381, Issue 4, 2008, Pages 956-974

  Maeda, Kenji ^a   Das, Debananda ^a   Yin, Philip D ^a   Tsuchiya, Kiyoto ^a   Ogata Aoki, Hiromi ^b   Nakata, Hirotomo ^a   Norman, Rachael B ^a   Hackney, Lauren A ^a   Takaoka, Yoshikazu ^c   Mitsuya, Hiroaki ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

Author keywords

allosteric inhibition; CCR5 inhibitor; extracellular loop; GPCR structure; HIV 1

Indexed keywords

1 BUT 2 YN 1 YL 3 (CYCLOHEXYLHYDROXYMETHYL) 9 (3,5 DIMETHYL 1 PHENYL 1H PYRAZOL 4 YLMETHYL) 1,4,9 TRIAZASPIRO (5.5)UNDECANE 2,5 DIONE]; 4 [4 [[1 BUTYL 3 (CYCLOHEXYLMETHYL) 2,5 DIOXO 1,4,9 TRIAZASPIRO[5.5] UNDEC 9 YL]METHYL]PHENOXY]BENZOIC ACID; AK 317; AK 530; AMINO ACID; APLAVIROC; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN GP 120; PIPERAZINEDIONE; VIRUS FUSION PROTEIN;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL FUSION; CHEMICAL STRUCTURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR DYNAMICS; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN MOTIF; RECEPTOR BINDING; STRUCTURE ANALYSIS; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 48649101575     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.06.041     Document Type: Article

References (57)

1. Raport C.J., Gosling J., Schweickart V.L., Gray P.W., and Charo I.F. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J. Biol. Chem. 271 (1996) 17161-17166
2. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
3. Wu L., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384 (1996) 179-183
4. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 (1996) 184-187
5. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
6. Kilby J.M., and Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348 (2003) 2228-2238
7. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA 96 (1999) 5698-5703
8. Maeda K., Yoshimura K., Shibayama S., Habashita H., Tada H., Sagawa K., et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 276 (2001) 35194-35200
9. Watson C., Jenkinson S., Kazmierski W., and Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67 (2005) 1268-1282
10. Tagat J.R., McCombie S.W., Nazareno D., Labroli M.A., Xiao Y., Steensma R.W., et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors: IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluo romethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 47 (2004) 2405-2408
11. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005) 4721-4732
12. Seto M., Aikawa K., Miyamoto N., Aramaki Y., Kanzaki N., Takashima K., et al. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J. Med. Chem. 49 (2006) 2037-2048
13. Imamura S., Ichikawa T., Nishikawa Y., Kanzaki N., Takashima K., Niwa S., et al. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity. J. Med. Chem. 49 (2006) 2784-2793
14. Maeda K., Nakata H., Koh Y., Miyakawa T., Ogata H., Takaoka Y., et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78 (2004) 8654-8662
15. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11 (2005) 1170-1172
16. Cormier E.G., and Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76 (2002) 8953-8957
17. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., et al. Structure of a V3-containing HIV-1 gp120 core. Science 310 (2005) 1025-1028
18. Kondru R., Zhang J., Ji C., Mirzadegan T., Rotstein D., Sankuratri S., and Dioszegi M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73 (2008) 789-800
19. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 97 (2000) 5639-5644
20. Nishikawa M., Takashima K., Nishi T., Furuta R.A., Kanzaki N., Yamamoto Y., and Fujisawa J. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob. Agents Chemother. 49 (2005) 4708-4715
21. Seibert C., Ying W., Gavrilov S., Tsamis F., Kuhmann S.E., Palani A., et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349 (2006) 41-54
22. Maeda K., Das D., Ogata-Aoki H., Nakata H., Miyakawa T., Tojo Y., et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281 (2006) 12688-12698
23. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77 (2003) 5201-5208
24. Nakata H., Maeda K., Miyakawa T., Shibayama S., Matsuo M., Takaoka Y., et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. J. Virol. 79 (2005) 2087-2096
25. Wu L., LaRosa G., Kassam N., Gordon C.J., Heath H., Ruffing N., et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186 (1997) 1373-1381
26. Samson M., LaRosa G., Libert F., Paindavoine P., Detheux M., Vassart G., and Parmentier M. The second extracellular loop of CCR5 is the major determinant of ligand specificity. J. Biol. Chem. 272 (1997) 24934-24941
27. Okada T., Sugihara M., Bondar A.N., Elstner M., Entel P., and Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J. Mol. Biol. 342 (2004) 571-583
28. Gether U., and Kobilka B.K. G protein-coupled receptors: II. Mechanism of agonist activation. J. Biol. Chem. 273 (1998) 17979-17982
29. Farrens D.L., Altenbach C., Yang K., Hubbell W.L., and Khorana H.G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274 (1996) 768-770
30. Okada T., Fujiyoshi Y., Silow M., Navarro J., Landau E.M., and Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl Acad. Sci. USA 99 (2002) 5982-5987
31. Siciliano S.J., Kuhmann S.E., Weng Y., Madani N., Springer M.S., Lineberger J.E., et al. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J. Biol. Chem. 274 (1999) 1905-1913
32. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
33. Rosenkilde M.M., and Schwartz T.W. GluVII:06-a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr. Top. Med. Chem. 6 (2006) 1319-1333
34. Ballesteros J.A., Jensen A.D., Liapakis G., Rasmussen S.G., Shi L., Gether U., and Javitch J.A. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 276 (2001) 29171-29177
35. Olson W.C., Rabut G.E., Nagashima K.A., Tran D.N., Anselma D.J., Monard S.P., et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73 (1999) 4145-4155
36. Lee B., Sharron M., Blanpain C., Doranz B.J., Vakili J., Setoh P., et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274 (1999) 9617-9626
37. 2 adrenergic G-protein-coupled receptor. Nature 450 (2007) 383-387
38. Sherman W., Day T., Jacobson M.P., Friesner R.A., and Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49 (2006) 534-553
39. Kuhmann S.E., Pugach P., Kunstman K.J., Taylor J., Stanfield R.L., Snyder A., et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78 (2004) 2790-2807
40. Trkola A., Kuhmann S.E., Strizki J.M., Maxwell E., Ketas T., Morgan T., et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl Acad. Sci. USA 99 (2002) 395-400
41. Baba M., Miyake H., Wang X., Okamoto M., and Takashima K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 51 (2007) 707-715
42. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81 (2007) 2359-2371
43. Marozsan A.J., Kuhmann S.E., Morgan T., Herrera C., Rivera-Troche E., Xu S., et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338 (2005) 182-199
44. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., and Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361 (2007) 212-228
45. LaBranche C., Kitrinos K., Howell R., McDanal C., Harris S., Jeffrey J., and Demarest J. Targeting HIV Entry, 1st International Workshop, Bethesda, MD, December 2-3, Abstract 9 (2005)
46. Nishizawa R., Nishiyama T., Hisaichi K., Matsunaga N., Minamoto C., Habashita H., et al. Spirodiketopiperazine-based CCR5 antagonists: lead optimization from biologically active metabolite. Bioorg. Med. Chem. Lett. 17 (2007) 727-731
47. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66 (1992) 2232-2239
48. Maeda Y., Foda M., Matsushita S., and Harada S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J. Virol. 74 (2000) 1787-1793
49. Gartner S., Markovits P., Markovitz D.M., Kaplan M.H., Gallo R.C., and Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233 (1986) 215-219
50. Koyanagi Y., O'Brien W.A., Zhao J.Q., Golde D.W., Gasson J.C., and Chen I.S. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 241 (1988) 1673-1675
51. Jacobson M.P., Pincus D.L., Rapp C.S., Day T.J., Honig B., Shaw D.E., and Friesner R.A. A hierarchical approach to all-atom protein loop prediction. Proteins 55 (2004) 351-367
52. Xiang Z., and Honig B. Extending the accuracy limits of prediction for side-chain conformations. J. Mol. Biol. 311 (2001) 421-430
53. Kaminski G.A., Friesner R.A., Tirado-Rives J., and Jorgensen W.J. Evaluation and reparameterization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B 105 (2001) 6474-6487
54. Still W.C., Tempczyk A., Hawley R.C., and Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 112 (1990) 6127-6129
55. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., et al. Glide: a new approach for rapid, accurate docking and scoring: 1. Method and assessment of docking accuracy. J. Med. Chem. 47 (2004) 1739-1749
56. Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., et al. Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49 (2006) 6177-6196
57. Jeeninga R.E., Hoogenkamp M., Armand-Ugon M., de Baar M., Verhoef K., and Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 74 (2000) 3740-3751